P
Paolo Morandi
Publications - 2
Citations - 1825
Paolo Morandi is an academic researcher. The author has contributed to research in topics: Neoadjuvant therapy & Breast cancer. The author has an hindex of 2, co-authored 2 publications receiving 1538 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more
TL;DR: Pertuzumab and trastuzumAB without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile, which justifies further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer.
Journal ArticleDOI
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Milvia Zambetti,Mauro Mansutti,Patricia Gomez,Ana Lluch,Christian Dittrich,Claudio Zamagni,Eva Ciruelos,Lorenzo Pavesi,Vladimir Semiglazov,Elena De Benedictis,Fernando Gaion,Mario Bari,Paolo Morandi,Pinuccia Valagussa,Gianni Luca +14 more
TL;DR: The ECTO II study showed higher pCR rates in patients with ER− disease, and substituting capecitabine for fluorouracil in anthracycline/taxane-containing regimens appeared to be beneficial only in ER+ tumors.